Business
Devonian Health Group Announces Grant of Stock Options
Devonian Health Group Announces Grant of Stock Options Canada NewsWire QUEBEC , ...
About this update from Devonian Health Group, Inc.
[{"type":"text","content":"\n\n\nDevonian Health Group Announces Grant of Stock Options\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nQUEBEC, Dec. 19, 2025 /CNW/ - Devonian Health Group Inc. (\"Devonian\" or the \"Company\") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical Company specializing in the development of prescription drugs targeting inflammatory diseases today announced the grant of Stock Options.\n\n\n\n\n\n\n\nGrant of Stock Options\nThe Company announces that the Board of Directors has approved the granting of 2,948,056 stock options to directors and a consultant of the Company. Of the options, 2,798,056 were granted to directors of the Company. The Options are exercisable (''vested'') at a price of $0.18 on grant date, for a period of 10 years following the grant date.\nThe Board of Directors has also approved the granting of 385,950 stock options to employees of the Company as part of their performance bonus and as retainer. In addition, 100,000 stock options were granted to a research and development consultant.These options are vested on the following schedule: 25% on grant date and then 25% per year for 3 years.\nAbout Thykamine™\nThykamine™, the first pharmaceutical product issued from Devonian's SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.\nAbout Devonian\nDevonian Health Group Inc. is a clinical sta...